Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Phase of Trial: Phase IV
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Nelarabine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 30 Oct 2017 Status changed from recruiting to completed.
- 24 Apr 2017 Planned End Date changed from 18 Aug 2018 to 18 Oct 2017.
- 24 Apr 2017 Planned primary completion date changed from 18 Aug 2018 to 18 Oct 2017.